Back to Journals » Clinical Pharmacology: Advances and Applications » Volume 11

Metabolism and Excretion of Intravenous, Radio-Labeled Amisulpride in Healthy, Adult Volunteers

Authors Fox GM, Roffel AF, Hartstra J, Bussian LA, van Marle SP

Received 11 October 2019

Accepted for publication 16 November 2019

Published 2 December 2019 Volume 2019:11 Pages 161—169

DOI https://doi.org/10.2147/CPAA.S234256

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 2

Editor who approved publication: Professor Arthur Frankel


Gabriel M Fox,1 Ad F Roffel,2 Jan Hartstra,2 Linda A Bussian,3 Sjoerd P van Marle2

1Department of Clinical Development, Acacia Pharma Ltd, Cambridge, UK; 2PRA Health Sciences, Groningen, the Netherlands; 3Comedica Ltd, Cambridge, UK

Correspondence: Gabriel M Fox
Department of Clinical Development, Acacia Pharma Ltd, The Officers’ Mess, Duxford, Cambridge CB22 4QH, UK
Tel +44 1223 919760
Fax +44 1223 919769
Email gabrielfox@acaciapharma.com

Purpose: Intravenous amisulpride, a dopamine D2/D3 antagonist, has recently been shown in trials to be an effective antiemetic at low doses. This study was conducted to investigate the metabolism and elimination of a single dose of intravenous 14C-labeled amisulpride in healthy, adult volunteers.
Patients and methods: Six healthy male volunteers aged 18–65 years were given a single 10 mg dose of 14C-labeled amisulpride containing not more than 1.8 MBq of radioactivity, infused over 4 mins. Concentrations of amisulpride and total radioactivity were measured in plasma, whole blood, urine and feces at various time points up to 168 hrs after dosing. Metabolites detected in plasma, urine and feces were characterized using liquid chromatography tandem mass spectrometry (LC-MS/MS) with in-line radiometric detection.
Results: The mean recovery of radioactivity in excreta was 96.4% (range 92.0–98.5%), of which 73.6% (range 70.6–79.2%) was recovered from urine and 22.8% (range 18.9–25.7%) from feces. Four metabolites of amisulpride were detected in urine, representing 15.0% of the excreted dose; three of these were also present in feces, representing 6.1% of the excreted dose. No metabolites were detected in plasma. Excretion was initially rapid, with about two-thirds of the drug-related material eliminated within 12 hrs, primarily in the urine. A second, slower phase of excretion was predominantly fecal and was essentially complete by 96 hrs after dosing. The terminal plasma elimination half-life of parent amisulpride was 3.7 hrs and that of total 14C-labeled drug material was 4.2 hrs.
Conclusion: Intravenous amisulpride undergoes limited metabolism and is excreted primarily via the renal route.
Clinical trial registry number: ClinicalTrials.gov NCT02881840.

Keywords: amisulpride, antiemetics, metabolism, elimination, radio-labeled
 

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]